Advancement of clinical and microbiological research for diagnosis and treatment effects.


Standardised clinical trial services in pre-analytical, analytical and post-analytical procedures.


Initiation and deployment of clinical trials data base management systems.


Accredited theory based modules with practical training for clinicians and support staff.

Welcome to TASK!

About Us

TASK is a clinical research organisation based in Cape Town, South Africa with a focus on performing clinical trials. TASK provides assistance to efficiently conduct studies for diagnosis, treatment or prevention of tuberculosis, as well as other prevalent diseases such as asthma, osteoarthritis and vaccine studies, where new and improved treatments are urgently needed.

The company was founded in 2005 by Prof. Andreas Diacon to accelerate the development and evaluation of novel anti-tuberculosis drugs. TASK mainly collaborates with international NGOs, government funded consortia, academic centers and pharmaceutical companies on various drug development projects.

TASK now employs over 150 staff members, has invested in state of the art bio-safety level 3 laboratory capacity as well as a network of clinical sites in Cape Town and the Western Cape.


Vision and Mission

Better healthcare starts with us. TASK provides a platform for the development of novelties in healthcare that benefit the community.


We want to be excellent. Do our work right and on time, every time. We own up, learn, and improve each day. We are TASK.


The Western Cape is home to diverse population groups, this coupled with first world infrastructure and TASK clinical expertise and experience, provides an ideal setting for clinical research.

We believe in community


Current Treatment Stand

Furthermore, TB is increasingly becoming resistant to the current treatment

New TB Drugs In The Pipeline

There are currently at least 12 drugs in various stages of clinical evaluation for TB

Clinical Studies

We do many clinical studies, click to read more about it.

Asthma Trials

We are looking for children and adults to participate.

TB Research

Tuberculosis is one of the major causes of disability and death worldwide.


Tuberculosis is one of the major causes of disability and death worldwide.
TB is currently the leading cause of death from a single infectious agent (above HIV/AIDS). In 2017, TB caused an estimated 1.6 million deaths worldwide. In the same year an estimated 10.0 million people developed TB globally (WHO Global TB report, 2018). South Africa remains one of the World Health Organization’s 30 high TB-burden countries contributing 3% to the global TB burden, with close to 800 people out of every 100 000 of the country’s population developing a new case of TB yearly (South African Health Review, 2018).
TB is a leading cause of death for people infected with HIV.
In 2015, 1 in 3 HIV deaths was due to TB. Globally in 2014, an estimated 480, 000 people developed multidrug-resistant TB (MDR-TB).
TASK is part of the global research community that is committed to finding new ways to better understand, diagnose, treat, and ultimately prevent TB.


Covid-19 BCG vaccine trial

04/05/20 PRESS RELEASE – immediate BCG Vaccine Clinical Trial in response to Covid-19 pandemic TASK008 – A placebo-controlled adaptive randomized controlled trial   Caption of press photo: TASK nurse injects the first participant, watched closely by study leader Dr Caryn Upton and Professor Andreas Diacon, founder and CEO of TASK.   TASK has just injected the…

Read more

New articles in the NEJM, Covid-19 & vaccine trials

While the world’s social media is inundated with populist commentary on the coronavirus, here is a tempered comment on what our appropriate response should be. #coronavirus #vaccines” Above article refers to Bill Gate’s position on Covid-19. In this he mentioned the importance of vaccines. A vaccine to interrupt the transmission of tuberculosis is also…

Read more